Clinical Trial Search

Primary: Number of Participants With Inhibitory Antibodies Against Coagulation Factor VIII (FVIII) ≥0.6 Bethesda Units — 0; 0 Participants

Primary: Difference in the Percent Change in Fasting Nuclear Factor Kappa-light-chain-enhancer of Activated B Cells Activation (DNA Binding Activity) in Mononuclear Cells Before…

Primary: Efficacy: Percent of Treatment Responders — 136 Participants

Primary: Change From Baseline in Hemoglobin A1C (A1C) at Week 12 — -0.99; -1.33 percentage of A1C — p=0.10

Primary: Percentage of Participants Achieving an Assessment of Spondyloarthritis International Society 40 (ASAS40) Response — 12.5; 25.4; 30.6 Percentage of participants — p=0.017

Primary: Daily Average Fatigue Intensity Score — 3.9; 4.4; 3.2; 2.3 units on a scale

Primary: Changes in Soft Tissues Around Implant — 243.89 root mean square in µm

Primary: Difference in the Change From Baseline in Fasting Blood Glucose Between KQ-791 and Placebo — -3.28; -3.93; 0.67; 3.17 mg/dL milligrams per deciliters

Primary: Change From Baseline in Daily Average Frequency of Daytime Urinary Incontinence Episodes — -1.30; -1.30; -1.34 urinary incontinence episodes per day — p=0.9949

Primary: Mean Pain Score Experienced During Version — 5.486; 5.433 score on a scale — p=0.943

Primary: Change in Spontaneous Pain at 60-120 Minutes After Lidocaine Infusion Initiated (Assessed on 0-10 NRS) — 33; 51 percentage of pain change from baseline — p=0.03

Primary: Working Memory Assessed by Domain Deficit Score — .29; .21; .14; .26 Score on a scale — p=0.039

Primary: Change From Baseline in A1C at Week 24 — -0.02; -0.39; -0.37 Percentage of A1C — p=< 0.001

Primary: Insulin Sensitivity — 1.7; 2.2 unitless

Primary: PUFA Levels in Normal and Metastatic Breast Tissue — 60.986; 72.762; 3.232; 3.505 ug/ml